The subject should have completed participation in the MEND-PNPO study (Protocol # 16002) and in the opinion of the Principal Investigator would benefit from long-term treatment with MC-1
Written informed consent (by parent or guardian if under the age of 18)
You may not be if
The patient has any condition or abnormality which may, in the opinion of the Investigator, compromise the safety of the patient, or influence their ability to comply with study procedures.
